ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

NCCS Networker Volume 1 Issue 2, Summer 1987

June 13, 1987

Zerhouni Appoints Two Institute Directors

September 13, 2002

Better Access Key To Higher Survival For African-Americans With Colon Cancer

August 30, 2002

FDA Selects 23 Survivors To Review Drug Applications.

June 15, 2001

In Brief: Obey Was Right- Tests On 70 Chemical Would Have Been Aborted Under NCI Budget

July 20, 1979